MET and non-small cell lung carcinoma: In NSCLC with MET amplification-driven resistance to epidermal growth factor receptor (EGFR) inhibitors, the combination of tepotinib plus gefitinib showed anti-tumor activity in the INSIGHT study [13], and clinical activity of tepotinib plus osimertinib is being evaluated in the INSIGHT 2 study (NCT03940703).